Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose

被引：15
作者：
Suarez-Kurtz, Guilherme [1 ]
Perini, Jamila A. [1 ]
Silva-Assuncao, Edimilson [1 ]
Struchiner, Claudio J. [1 ]
机构：
[1] Inst Nacl Canc, Div Farmacol, BR-21230050 Rio De Janeiro, Brazil
来源：
BLOOD | 2009年 / 113卷 / 17期
关键词：
POLYMORPHISMS; REQUIREMENTS;
D O I：
10.1182/blood-2009-01-200600
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4125 / 4126
页数：2
相关论文
共 50 条
  • [1] Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy
    Li, Chun
    Schwarz, Ute I.
    Ritchie, Marylyn D.
    Roden, Dan M.
    Stein, C. Michael
    Kurnik, Daniel
    BLOOD, 2009, 113 (17) : 3925 - 3930
  • [2] Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations
    Gan, Gin Gin
    Phipps, Maude E.
    Lee, Michael M. T.
    Lu, Liang S.
    Subramaniam, Rajallectchumy Y.
    Bee, Ping C.
    Chang, Sean H.
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 635 - 641
  • [3] A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age
    Hamberg, A-K
    Wadelius, M.
    Lindh, J. D.
    Dahl, M. L.
    Padrini, R.
    Deloukas, P.
    Rane, A.
    Jonsson, E. N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) : 727 - 734
  • [4] Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients
    Natarajan, Sripriya
    Ponde, Chandrashekhar K.
    Rajani, Rajesh M.
    Jijina, Farah
    Gursahani, Roopkumar
    Dhairyawan, Pradnya P.
    Ashavaid, Tester F.
    PHARMACOLOGICAL REPORTS, 2013, 65 (05) : 1375 - 1382
  • [5] Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping
    Maurice, Carleta B.
    Barua, Pankaj K.
    Simses, Diane
    Smith, Penny
    Howe, John G.
    Stack, Gary
    CLINICA CHIMICA ACTA, 2010, 411 (13-14) : 947 - 954
  • [6] Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients
    Huang, Sheng-Wen
    Chen, Hai-Sheng
    Wang, Xian-Qun
    Huang, Ling
    Xu, Ding-Li
    Hu, Xiao-Jia
    Huang, Zhi-Hui
    He, Yong
    Chen, Kai-Ming
    Xiang, Dao-Kang
    Zou, Xiao-Ming
    Li, Qinag
    Ma, Li-Qin
    Wang, Hao-Fei
    Chen, Bao-Lin
    Li, Liang
    Jia, Yan-Kai
    Xu, Xiang-Min
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (03) : 226 - 234
  • [7] Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin
    Fung, Erik
    Patsopoulos, Nikolaos A.
    Belknap, Steven M.
    O'Rourke, Daniel J.
    Robb, John F.
    Anderson, Jeffrey L.
    Shworak, Nicholas W.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08) : 893 - 904
  • [8] VKORC1 and CYP2C9 Genotypes are Predictors of Warfarin-Related Outcomes in Children
    Shaw, Kaitlyn
    Amstutz, Ursula
    Hildebrand, Claudette
    Rassekh, S. Rod
    Hosking, Martin
    Neville, Kathleen
    Leeder, J. Steven
    Hayden, Michael R.
    Ross, Colin J.
    Carleton, Bruce C.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 1055 - 1062
  • [9] CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation
    Junior Lima Santos, Paulo Caleb
    Dinardo, Carla Luana
    Schettert, Isolmar Tadeu
    Gadi Soares, Renata Alonso
    Kawabata-Yoshihara, Liz
    Bensenor, Isabela Martins
    Krieger, Jose Eduardo
    Lotufo, Paulo Andrade
    Pereira, Alexandre Costa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 789 - 797
  • [10] Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population
    Ozer, Mahmut
    Demirci, Yeliz
    Hizel, Candan
    Sarikaya, Sabit
    Karalti, Iskender
    Kaspar, Cigdem
    Alpan, Serdar
    Genc, Ece
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 112 (03) : 209 - 214
12345